{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:33:48Z","timestamp":1790948028546,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,5,7]],"date-time":"2014-05-07T00:00:00Z","timestamp":1399420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10549-014-2980-0","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T16:01:35Z","timestamp":1399392095000},"page":"707-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":159,"title":["Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and\/or ovarian cancer syndrome testing"],"prefix":"10.1007","volume":"145","author":[{"given":"Priyanka","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Klemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce F.","family":"Kimler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Mahnken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qamar J.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manana","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol S.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilee K.","family":"McGinness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M. W.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Ranallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane R.","family":"Stecklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy A.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol J.","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K.","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,7]]},"reference":[{"key":"2980_CR1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinus H, Thorlacius S, Eerola H, Nevalinna H, Syrjakowski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117\u20131130. doi: 10.1086\/375033","journal-title":"Am J Hum Genet"},{"key":"2980_CR2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329\u20131333. doi: 10.1200\/JCO.2006.09.1066","journal-title":"J Clin Oncol"},{"key":"2980_CR3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowits M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Sid LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF, EMBRACE (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812\u2013822. doi: 10.1093\/jnci\/djt095","journal-title":"J Natl Cancer Inst"},{"key":"2980_CR4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","volume":"28","author":"T Byrski","year":"2010","unstructured":"Byrski T, Gronwald J, Huzarski T, Grzbowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375\u2013379. doi: 10.1200\/JCO.2008.20.7019","journal-title":"J Clin Oncol"},{"key":"2980_CR5","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0959-8049(00)00303-8","volume":"36","author":"M Esteller","year":"2000","unstructured":"Esteller M (2000) Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36:2294\u20132300. doi: 10.1016\/S0959-8049(00)00303-8","journal-title":"Eur J Cancer"},{"key":"2980_CR6","doi-asserted-by":"crossref","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin GJS, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Macpherson E, Dougherty B, Jurgensmeier JM, Orr M, Matulonis U (2013) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 31:5505","DOI":"10.1200\/jco.2013.31.15_suppl.5505"},{"key":"2980_CR7","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylansa L, Riisnaes R, Foster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Lannone R, Kaye SB, Bono JS, Wenham RM (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14:882\u2013892. doi: 10.1016\/S1470-2045(13)70240-7","journal-title":"Lancet Oncol"},{"key":"2980_CR8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Gerber JE (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145\u20131153. doi: 10.1200\/JCO.2009.22.4725","journal-title":"J Clin Oncol"},{"key":"2980_CR9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235\u2013244. doi: 10.1016\/S0140-6736(10)60892-6","journal-title":"Lancet"},{"key":"2980_CR10","doi-asserted-by":"crossref","first-page":"10692","DOI":"10.1158\/0008-5472.CAN-05-1277","volume":"65","author":"M Wei","year":"2005","unstructured":"Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI (2005) BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65:10692\u201310699","journal-title":"Cancer Res"},{"key":"2980_CR11","unstructured":"11. NICE clinical guideline (2013) 164: Familial breast cancer, National Institutes for Health and Care Excellence. http:\/\/guidance.nice.org.uk\/CG164 . Accessed 10 April 2014"},{"issue":"Suppl 6","key":"2980_CR12","doi-asserted-by":"crossref","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","volume":"22","author":"J Balmana","year":"2011","unstructured":"Balmana J, Diez O, Rubio IT, Cardoso F (2011) BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 22(Suppl 6):vi31\u2013vi34","journal-title":"Ann Oncol"},{"key":"2980_CR13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc2054","volume":"12","author":"JD Fackenthal","year":"2007","unstructured":"Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 12:937\u2013948. doi: 10.1038\/nrc2054","journal-title":"Nat Rev Cancer"},{"key":"2980_CR14","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Alguno AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282\u20134288. doi: 10.1200\/JCO.2008.16.6231","journal-title":"J Clin Oncol"},{"key":"2980_CR15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/PAS.0b013e31819c1c93","volume":"33","author":"LC Collins","year":"2009","unstructured":"Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE (2009) Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 33:1093\u20131097. doi: 10.1097\/PAS.0b013e31819c1c93","journal-title":"Am J Surg Pathol"},{"key":"2980_CR16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-011-1433-2","volume":"129","author":"E Comen","year":"2011","unstructured":"Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M (2011) Relative contributions of BRCA1 and BRCA2 mutations to \u201ctriple-negative\u201d breast cancer in Ashkenazi Women. Breast Cancer Res Treat 129:185\u2013190. doi: 10.1007\/s10549-011-1433-2","journal-title":"Breast Cancer Res Treat"},{"key":"2980_CR17","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","volume":"95","author":"WD Foulkes","year":"2003","unstructured":"Foulkes WD, Stefansson IM, Chappuis PO, B\u00e9gin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482\u20131485. doi: 10.1093\/jnci\/djg050","journal-title":"J Natl Cancer Inst"},{"key":"2980_CR18","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills BG, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082\u20131089. doi: 10.1158\/1078-0432","journal-title":"Clin Cancer Res"},{"key":"2980_CR19","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/cncr.26576","volume":"118","author":"AR Hartman","year":"2012","unstructured":"Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118:2787\u20132795. doi: 10.1002\/cncr.26576","journal-title":"Cancer"},{"key":"2980_CR20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370. doi: 10.1038\/nature11412","journal-title":"Nature"},{"key":"2980_CR21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-9-86","volume":"9","author":"S Young","year":"2009","unstructured":"Young S, Pilarski R, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakill I, Royer R, Li S, Narod SA (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86. doi: 10.1186\/1471-2407-9-86","journal-title":"BMC Cancer"},{"key":"2980_CR22","doi-asserted-by":"crossref","first-page":"e38361","DOI":"10.1371\/journal.pone.0038361","volume":"7","author":"P Meyer","year":"2012","unstructured":"Meyer P, Landgraf K, Hogel B, Eiermann W, Ataseven B (2012) BRCA2 mutations and triple-negative breast cancer. PLoS One 7:e38361. doi: 10.1371\/journal.pone.0038361","journal-title":"PLoS One"},{"key":"2980_CR23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/bjc.2012.31","volume":"106","author":"L Robertson","year":"2012","unstructured":"Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans DG, Ross G, Eccles D, Tutt A, Rahman N (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50\u00a0years. Br J Cancer 106:1234\u20131238. doi: 10.1038\/bjc.2012.31","journal-title":"Br J Cancer"},{"key":"2980_CR24","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic\/Familial High-Risk Assessment: Breast and Ovarian, (ed 4.2013), National Comprehensive Cancer Network. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed 10 April 2014"},{"key":"2980_CR25","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","volume":"27","author":"JS Kwon","year":"2010","unstructured":"Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 27:4214\u20134220. doi: 10.1200\/JCO.2010.28.0719","journal-title":"J Clin Oncol"},{"key":"2980_CR26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/GIM.0b013e31822a8113","volume":"13","author":"G Wang","year":"2011","unstructured":"Wang G, Beattie MS, Ponce NA, Phillips KA (2011) Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med 13:1045\u20131050. doi: 10.1097\/GIM.0b013e31822a8113","journal-title":"Genet Med"},{"key":"2980_CR27","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American society of clinical oncology\/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784\u20132795. doi: 10.1200\/JOP.777003","journal-title":"J Clin Oncol"},{"key":"2980_CR28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u2013381. doi: 10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"2980_CR29","unstructured":"29. U. S. Census Bureau (2010) Census Data, 2010 Census Briefs. http:\/\/www.census.gov\/2010census\/data\/ . Accessed 10 April 2014"},{"key":"2980_CR30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2009.27.0660","volume":"5","author":"ME Robson","year":"2010","unstructured":"Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K (2010) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 5:893\u2013901. doi: 10.1200\/JCO.2009.27.0660","journal-title":"J Clin Oncol"},{"key":"2980_CR31","unstructured":"31. American Society of Breast Surgeons (2012) Position Statement on BRCA Genetic Testing for Patients With and Without Breast Cancer. American Society of Breast Surgeons. https:\/\/www.breastsurgeons.org\/statements\/PDF_Statements\/BRCA_Testing.pdf . Accessed 11 April 2014"},{"key":"2980_CR32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10897-012-9547-1","volume":"22","author":"JL Berliner","year":"2013","unstructured":"Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmans T (2013) NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns 22:155\u2013163. doi: 10.1007\/s10897-012-9547-1","journal-title":"J Genet Couns"},{"key":"2980_CR33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.7326\/0003-4819-143-5-200509060-00011","volume":"143","author":"US Preventive Task Force","year":"2005","unstructured":"US Preventive Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation. Ann Intern Med 143:355\u2013361. doi: 10.7326\/0003-4819-143-5-200509060-00011","journal-title":"Ann Intern Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2980-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-2980-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2980-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T02:32:53Z","timestamp":1597804373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-2980-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,7]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2980"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-2980-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,7]]}}}